alexa Intravitreal Bevacizumab Injection as a Primary Therapy for Threshold Disease (ROP) in Al Qassim Region | OMICS International
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Intravitreal Bevacizumab Injection as a Primary Therapy for Threshold Disease (ROP) in Al Qassim Region

Abdelrahman Gaber Salman*
Abdelrahman Gaber Salman, Lecturer of ophthalmology, Ophthalmology department -Ain Shams University, Egypt
Corresponding Author : Abdelrahman Gaber Salman
Lecturer of ophthalmology
Ophthalmology department-Ain Shams University, Egypt
Tel: 0020161616730, 00966551228104
E-mail: [email protected]
Received September 13, 2010; Accepted October 19, 2010; Published October 21, 2010
Citation: Salman AG (2010) Intravitreal Bevacizumab Injection as a Primary Therapy for Threshold Disease (ROP) in Al Qassim Region. J Clinic Experiment Ophthalmol 1:113. doi:10.4172/2155-9570.1000113
Copyright: © 2010 Salman AG. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Abstract

Purpose: To evaluate the efficacy and safety of intravitreal injection of bevacizumab without laser as primary therapy in patients with threshold disease in difficulties or lack of facilities for laser as Al Qassim region. Patients and methods: The study included eighteen eyes of nine patients with moderate to severe active ROP (stage III, threshold, or plus disease in zones I and II). For all we gave intravitreal injection of bevacizumab without laser after obtained written consent from the parents, including disclosure of the off-label use of the drug, its unknown safety and efficacy for this indication, and its unknown effects in children. Results: Of 18 eyes enrolled in the study, all have completed 1-year follow-up. Mean birth weight in these infants was 1235 gm, mean gestational age at birth was 28.8 weeks, and mean age at the time of injection was 1.5 months. All eyes showed complete resolution of neovascular plus disease. No patient developed any ocular or systemic complications. In all cases, the ERG and VEP were within normal at 1 year. Conclusions: Intravitreal injection of bevacizumab is an easy, safe and effective modality of therapy for threshold disease ROP especially in presence of difficulties for laser photocoagulation.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version